𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The effects of tacrine on regional cerebral blood flow in Alzheimer's disease

✍ Scribed by John T. O'Brien; Ghulam M. S. Syed; Professor Raymond Levy

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
376 KB
Volume
7
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

Regional cerebral blood flow (rCBF) was studied in nine patients with Alzheimer's disease before and after trestment with tacrine. A small but significant improvement in cognitive functioning on the drug was not accompanied by significant changes in rCBF for the group as a whole. However, when the analysis was repeated excluding the only patient who showed no clinical response to the drug a significant increase in rCBF was seen to the right posterior temporal area. This preliminary study shows that some caution is necessary when interpreting studies of rCBF as changes in cognitive functioning may not always be accompanied by parallel changes in rCBF. Separate analysis of drug responders and non-responders may be a fruitful area for further research.

πŸ“œ SIMILAR VOLUMES

Long-term effects of tacrine in alzheime
Long-term effects of tacrine in alzheimer's disease: An open study
✍ Sarah A. Eagger; Marcus Richards; Professor Raymond Levy πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 407 KB

## Abstract To study the efficacy and safety of prolonged tacrine administration, we monitored 41 patients meeting NINCDS–ADRDA criteria for probable Alzheimer's disease while taking tacrine on an open basis for a period of up to 192 weeks. Dependent variables were the Abbreviated Mental Test Score

ACE inhibitor lacks acute effect on cogn
ACE inhibitor lacks acute effect on cognition or brain blood flow in alzheimer's disease
✍ Dr. Myron F. Weiner; Frederick J. Bonte; Ron Tintner; Neville Ford; Doris Svetli πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 296 KB

## Abstract The effects of the acute administration of the ACE inhibitor ceronapril were studied in 12 Alzheimer's disease (AD) patients and 2 age‐matched controls. A 4‐week open trial was performed with daily doses of 40–80 mg/day. Testing was performed at baseline and at 4 weeks using the Mini‐me